This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Edelstein, P. H.
Right arrow Articles by Gladue, R. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Edelstein, P. H.
Right arrow Articles by Gladue, R. P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, Feb 1996, 314-319, Vol 40, No. 2
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia

PH Edelstein, MA Edelstein, J Ren, R Polzer and RP Gladue
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104-4283, USA.

The activity of trovafloxacin against 22 clinical Legionella isolates was determined by broth microdilution susceptibility testing. The trovafloxacin concentration required to inhibit 90% of strains tested was < or = 0.004 micrograms/ml, in contrast to 0.032 micrograms/ml for ofloxacin. In guinea pig alveolar macrophages, trovafloxacin achieved intracellular levels up to 28-fold over the extracellular concentration, which was similar to the levels obtained with erythromycin. Trovafloxacin (0.25 micrograms/ml) reduced bacterial counts of two L. pneumophila strains grown in guinea pig alveolar macrophages by > 2 log10 CFU/ml, without regrowth, under drug-free conditions over a 3-day period; trovafloxacin was significantly more active than ofloxacin or erythromycin (0.25 to 1 microgram/ml) in this assay. Single-dose (10 mg of prodrug CP-116,517-27 per kg of body weight given intraperitoneally [i.p.], equivalent to 7.5 mg of trovafloxacin per kg) pharmacokinetic studies performed in guinea pigs with L. pneumophila pneumonia revealed peak serum and lung trovafloxacin levels to be 3.8 micrograms/ml and 5.0 micrograms/g, respectively, at 0.5 h and 4.2 micrograms/ml and 2.9 micrograms/g, respectively, at 1 h. Administration of a lower prodrug dose (1.4 mg of trovafloxacin equivalent per kg i.p.) gave levels in lung and serum of 0.4 microgram/g and 0.4 microgram/ml, respectively, 1 h after drug administration. The terminal half-lives of elimination from serum and lung were 0.8 and 1.1 h, respectively. All 15 infected guinea pigs treated for 5 days with CP-116,517-27 once daily (10 mg/kg/day i.p., equivalent to 7.5 mg of trovafloxacin per kg/day) survived for 10 days after antimicrobial therapy, as did all 15 guinea pigs treated with ofloxacin once daily (10 mg/kg/day i.p.) for 5 days. None of 13 animals treated with saline survived. In a second experiment with animals, trovafloxacin (1.4 mg/kg/day i.p. for 5 days) protected all 16 guinea pigs from death, whereas all 15 animals treated with saline died. Trovafloxacin is an effective antimicrobial agent against Legionella in vitro and in vivo, with the ability to concentrate in macrophages and kill intracellular organisms.


This article has been cited by other articles:

  • Almahmoud, I., Kay, E., Schneider, D., Maurin, M. (2009). Mutational paths towards increased fluoroquinolone resistance in Legionella pneumophila. J Antimicrob Chemother 64: 284-293 [Abstract] [Full Text]  
  • Seral, C., Barcia-Macay, M., Mingeot-Leclercq, M. P., Tulkens, P. M., Van Bambeke, F. (2005). Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages. J Antimicrob Chemother 55: 511-517 [Abstract] [Full Text]  
  • Roig, J., Rello, J. (2003). Legionnaires' disease: a rational approach to therapy. J Antimicrob Chemother 51: 1119-1129 [Abstract] [Full Text]  
  • Smith, R. P., Baltch, A. L., Michelsen, P. B., Ritz, W. J., Alteri, R. (2003). Use of the Microbial Growth Curve in Postantibiotic Effect Studies of Legionella pneumophila. Antimicrob. Agents Chemother. 47: 1081-1087 [Abstract] [Full Text]  
  • Edelstein, P. H., Weiss, W. J., Edelstein, M. A. C. (2003). Activities of Tigecycline (GAR-936) against Legionella pneumophila In Vitro and in Guinea Pigs with L. pneumophila Pneumonia. Antimicrob. Agents Chemother. 47: 533-540 [Abstract] [Full Text]  
  • Paillard, D., Grellet, J., Dubois, V., Saux, M.-C., Quentin, C. (2002). Discrepancy between Uptake and Intracellular Activity of Moxifloxacin in a Staphylococcus aureus-Human THP-1 Monocytic Cell Model. Antimicrob. Agents Chemother. 46: 288-293 [Abstract] [Full Text]  
  • Edelstein, P. H., Shinzato, T., Edelstein, M. A. C. (2001). BMS-284756 (T-3811ME) a new fluoroquinolone: in vitro activity against Legionella, efficacy in a guinea pig model of L. pneumophila pneumonia and pharmacokinetics in guinea pigs. J Antimicrob Chemother 48: 667-675 [Abstract] [Full Text]  
  • Edelstein, P. H., Higa, F., Edelstein, M. A. C. (2001). In Vitro Activity of ABT-773 against Legionella pneumophila, Its Pharmacokinetics in Guinea Pigs, and Its Use to Treat Guinea Pigs with L. pneumophila Pneumonia. Antimicrob. Agents Chemother. 45: 2685-2690 [Abstract] [Full Text]  
  • Edelstein, P. H., Shinzato, T., Doyle, E., Edelstein, M. A. C. (2001). In Vitro Activity of Gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and Its Pharmacokinetics in Guinea Pigs with L. pneumophila Pneumonia. Antimicrob. Agents Chemother. 45: 2204-2209 [Abstract] [Full Text]  
  • Jonas, D., Engels, I., Friedhoff, C., Spitzmuller, B., Daschner, F. D., Frank, U. (2001). Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular Legionella pneumophila. J Antimicrob Chemother 47: 147-152 [Abstract] [Full Text]  
  • Tullio, V., Cuffini, A. M., Bonino, A., Palarchio, A. I., Roana, J., Mandras, N., Rossi, V., Carlone, N. A. (2000). Influence of a new fluoroquinolone, AF3013 (the active metabolite of prulifloxacin), on macrophage functions against Klebsiella pneumoniae: an in vitro comparison with pefloxacin. J Antimicrob Chemother 46: 241-247 [Abstract] [Full Text]  
  • Ferguson, J., McEwen, J., Al-Ajmi, H., Purkins, L., Colman, P. J., Willavize, S. A. (2000). A comparison of the photosensitizing potential of trovafloxacin with that of other quinolones in healthy subjects. J Antimicrob Chemother 45: 503-509 [Abstract] [Full Text]  
  • den Broek, P. J. v., Koot, T. G. A., Strijen, E. v., Mattie, H. (1999). Intracellular activity of trovafloxacin against Staphylococcus aureus. J Antimicrob Chemother 44: 193-199 [Abstract] [Full Text]  
  • Ogtrop, M. L. v. (1999). The antibacterial efficacy of trovafloxacin against an experimental infection with Listeria monocytogenes in hydrocortisone-treated mice. J Antimicrob Chemother 44: 229-234 [Abstract] [Full Text]  
  • Dedicoat, M., Venkatesan, P. (1999). The treatment of Legionnaires' disease. J Antimicrob Chemother 43: 747-752 [Full Text]  
  • Ng, W., Lutsar, I., Wubbel, L., Ghaffar, F., Jafri, H., McCracken, G. H., Friedland, I. R. (1999). Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia. J Antimicrob Chemother 43: 811-816 [Abstract] [Full Text]  
  • Takahata, M., Mitsuyama, J., Yamashiro, Y., Yonezawa, M., Araki, H., Todo, Y., Minami, S., Watanabe, Y., Narita, H. (1999). In Vitro and In Vivo Antimicrobial Activities of T-3811ME, a Novel Des-F(6)-Quinolone. Antimicrob. Agents Chemother. 43: 1077-1084 [Abstract] [Full Text]  
  • Edelstein, P. H., Edelstein, M. A. C. (1999). In Vitro Activity of the Ketolide HMR 3647 (RU 6647) for Legionella spp., Its Pharmacokinetics in Guinea Pigs, and Use of the Drug To Treat Guinea Pigs with Legionella pneumophila Pneumonia. Antimicrob. Agents Chemother. 43: 90-95 [Abstract] [Full Text]  
  • Bédos, J.-P., Rieux, V., Bauchet, J., Muffat-Joly, M., Carbon, C., Azoulay-Dupuis, E. (1998). Efficacy of Trovafloxacin against Penicillin-Susceptible and Multiresistant Strains of Streptococcus pneumoniae in a Mouse Pneumonia Model. Antimicrob. Agents Chemother. 42: 862-867 [Abstract] [Full Text]  
  • Kaatz, G. W., Seo, S. M., Aeschlimann, J. R., Houlihan, H. H., Mercier, R.-C., Rybak, M. J. (1998). Efficacy of Trovafloxacin against Experimental Staphylococcus aureus Endocarditis. Antimicrob. Agents Chemother. 42: 254-256 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»